ASX ANNOUNCEMENT

ASX:VHL

30th October 2026

Vitasora Secures Major US Healthcare Contract and A$3 Million Working Capital Facility

Highlights

- **Major new US healthcare contract:** Treasure Coast Community Health (TCCH), with seven Florida locations and approximately 31,000 patients, adds an initially addressable population of approximately 9,000 Medicare patients, providing a significant new opportunity beyond existing customer growth.
- **October billable care minutes up 50%:** Estimate **~263,000 billable** care minutes expected in October, compared with approximately 175,000 in September, which itself grew 20% on August.
- **October revenue momentum:** Revenue is estimated at approximately **US$450,000,** equivalent to an illustrative annualised run-rate of US$5.4 million **(~A$8.1 million**), already **~90%** above FY26 revenue of A$4.29 million. Further growth is anticipated as existing operations expand and new clients commence. The run-rate is an estimate, not a forecast.
- **High Care Coordinator utilisation:** Has exceeded 95% on recent operating days, supporting productivity and the potential for operating leverage as capacity expands.
- **First fully integrated vCare deployment:** TCCH will become the first customer to implement Vitasora's complete vCare care-management platform integrated with its electronic medical records (EMR), supporting improved productivity, revenue capture and operating efficiency.
- **Capacity for further growth:** Vitasora has 42 Care Coordinators in place and is targeting 48 by November 2026 and approximately 115 during Q1 2027, subject to recruitment and demand.
- **Binding A$3 million secured facility:** Strategic cornerstone shareholder Peters Investments Pty Ltd has entered into a binding working capital facility terms sheet for a A$3 million secured loan and option facility. Long-form documents are being finalised and funding remains subject to conditions.

Major TCCH Contract Adds New Growth Opportunity

Vitasora Health Limited (ASX: VHL; OTCQB: VHLUF) ("Vitasora" or "the Company") is pleased to announce a major new healthcare services agreement with Treasure Coast Community Health (TCCH), a Florida community health centre operating seven locations, serving approximately 31,000 patients and delivering more than 125,000 patient encounters annually.

The agreement provides access to an initially addressable Medicare population of approximately 9,000 patients. It comes as Vitasora's existing US operations are accelerating, with October billable care minutes on track to grow more than 50% following an approximate 20% growth in September. The addressable population is not a forecast of enrolments.

The initial program will deliver Chronic Care Management (CCM) and Principal Care Management (PCM), supported by Vitasora's THRIVE care-management model and V-care technology. Patient enrolments are targeted to commence during November 2026, with an initial campaign planned to begin before of Christmas.

The TCCH relationship represents incremental potential recurring revenue beyond the growth already being produced by Vitasora's existing clients. Vitasora's current Florida based CCM clients currently generate approximately US$70–100 per patient per month, depending on care needs. Vitasora enters this new agreement with a strengthened management team, established clinical workforce and technology infrastructure designed to implement new customers more efficiently and at scale.

Commenting on the partnership, Dr. Heather Miranda, CEO of Treasure Coast Community Health, said:

"The best health outcomes happen when patients, providers, and support teams work together. Through our partnership with Vitasora Health, we're able to give patients additional support between visits, helping them stay connected to their care plan, and make lasting changes that support better health." Dr. Heather Miranda, DrPH, MHA, RD, LDN, CEO Treasure Coast Community Health.

Vitasora's THRIVE Model: Improving Patient Outcomes and Delivering Potential Healthcare Savings

Healthcare providers choose Vitasora's THRIVE model to extend care beyond clinic visits, improve patient engagement and clinical outcomes, and reduce the burden on physicians. For Medicare and other payors, better chronic disease management offers the potential to reduce avoidable hospitalisations and healthcare costs, with modelled savings of **US$3–US$8 for every US$1 spent on connected care services.**

Vitasora is already demonstrating encouraging patient outcomes across its existing client base. In a recent three-month period, patients recorded an average 8.5-point reduction in systolic blood pressure, with 70% showing improvement and 35% returning to the controlled range. Based on published research, a reduction of this magnitude could translate into a **23–25% lower risk of stroke and a 16–18% lower risk of major cardiovascular events**, reinforcing the potential for better patient outcomes and meaningful healthcare cost savings.

Billable Care Minutes Accelerate, Supporting Revenue Growth

Vitasora continues to deliver strong growth in billable care minutes, a key driver of revenue, supported by an expanding Care Coordinator workforce, higher productivity and improved efficiencies through its vCare platform.

October billable care minutes are on track to increase by more **than 50% over September**, reaching approximately **263,000 minutes**, compared with 175,000 in September, which itself represented 20% growth over August. Care Coordinator utilisation has consistently exceeded 95% during October. Importantly, this growth has been generated entirely from existing clients, ahead of the commencement of TCCH patient enrolments and anticipated new client contributions.

Management estimates October revenue at approximately **US$450,000**, equivalent to an illustrative annualised revenue run-rate of **US$5.4 million (A$8.1 million)**, almost **90% above FY2026 audited revenue of A$4.29 million**. This represents Vitasora's current operating scale, with further

growth anticipated as additional Care Coordinators are employed, become productive and new client contracts commence.

Vitasora currently has **42 Care Coordinators**, targeting **48 by November 2026 and approximately 115 during Q1 2027**, with recruitment aligned to patient demand. Under management's operating assumptions, each fully productive Care Coordinator has the capacity to generate approximately **US$595 in daily revenue**, providing significant operating leverage as the workforce expands.

Management expects this growth, combined with increasing productivity and vCare efficiencies, to drive **pro forma operating profitability ahead of cash-flow breakeven**, reflecting the timing difference between revenue generation and cash collections. The Company continues to target **cash-flow breakeven in H1 2027**, subject to operational execution, patient enrolments, collections and funding availability.

Note: October figures are management estimates based on operating and billing activity and remain subject to reconciliation and statutory revenue recognition. The annualised run-rate is illustrative, based on a single month's estimated activity, and is not a revenue forecast. The comparison with FY2026 audited revenue is indicative only and uses an exchange rate of US$0.667 per A$1. Workforce targets and profitability expectations are forward-looking and subject to execution and market conditions.

vCare: Proven Technology Supporting TCCH Scalable Growth

TCCH will become Vitasora's first customer to implement its complete V-care care-management solution integrated directly with the customer's Electronic Medical Record System (EMR). Vitasora has already successfully implemented vCare across its existing US client base, where the platform is fully operational and supporting daily care delivery and billing activities. TCCH will therefore benefit from an established and proven platform, rather than an untested technology deployment, substantially reducing implementation risk.

vCare integrates patient information, clinical workflows, Care Coordinator allocation, patient prioritisation and billing support into a single platform designed for scalable connected-care delivery.

The platform enables appropriately qualified Care Coordinators to support patients across healthcare organisations, improving workforce flexibility, productivity and continuity of care. Integrated documentation and billing workflows also support more efficient conversion of eligible care activity into billable revenue while controlling the incremental costs of expansion.

The TCCH implementation represents a major milestone in deploying the integrated operating model Vitasora has developed to support efficient growth across its US healthcare customer base.

A$3 Million Secured Facility

Vitasora has entered into a binding terms sheet for a A$3 million secured loan facility with Peters Investments Pty Ltd, a cornerstone investor in the Company's A$4 million June 2026 capital raising. Drawdown is conditional on the parties entering into a formal loan agreement and agreeing on the terms of a general security deed (**General Security Deed**), both of which are being finalised.

The agreed terms provide for a 24-month loan with interest at 12.5% per annum, compounded daily and payable monthly in cash, supported by a first-ranking General Security Deed over the Company and its Australian subsidiaries, subject to shareholder approval for the purposes of ASX Listing Rule 10.1. Principal is repayable at maturity; early repayment attracts a 6% fee on principal repaid. Drawdown remains subject to applicable conditions.

The option package comprises 208,971,000 four-year options, initially exercisable at A$0.012 per share, subject to adjustment if the Company issues shares for cash during the option term at a price below the prevailing exercise price, in which case the exercise price will reduce to that issue price. The options are also subject to a floor price of A$0.004 and ASX confirmation that the option terms are appropriate and equitable under Listing Rule 6.1.

The stated 19.9% ownership outcome on full exercise remains subject to capitalisation verification and applicable approvals. The Options cannot be exercised to the extent this would breach the 20% takeover threshold contained in section 606 of the Corporations Act 2001 (Cth).

The Company will seek approval of its shareholders at a general meeting to be held within 3 months after drawdown for the grant of security under Listing Rule 10.1 and the issue of the Options under Listing Rule 7.1. An independent expert's report will be commissioned for the Listing Rule 10.1 resolution. If either approval is not obtained, the Company must repay the loan within 30 days after the meeting, together with accrued interest and an amount equal to 6% of the loan amount.

The material terms and conditions of the secured loan facility are set out in the Annexure to this announcement.

Proceeds are intended to support TCCH and other client implementations, Care Coordinator recruitment, patient enrolments and working capital. The facility also includes restrictions on additional indebtedness and security, as summarised in the annex.

Subject to documentation, drawdown and operating performance, management expects the facility to support expansion and its H1 2027 cash-flow breakeven objective.

The facility is intended to fund growth without an immediate ordinary share issue.

Vitasora Health Managing Director and CEO, Marjan Mikel, said:

"What is particularly encouraging is that our growth is not just continuing — it is accelerating. We are on track for more than 50% growth in billable care minutes during October, following approximately 20% growth in September. This reflects the work of our team and the improvements we have made to our operating model."

"TCCH is a significant addition to our US business, bringing approximately 9,000 addressable Medicare patients and substantial potential recurring revenue opportunities on top of the growth we are already generating."

"We are pleased that Peters Investments continue to back Vitasora as a cornerstone investor, with this binding A$3 million facility agreement. This continued backing reflects confidence in the progress our team has delivered and the opportunity ahead."

"The facility is designed to fund our next phase of growth without an immediate equity raising as we work towards cash-flow breakeven in H1 2027."

With TCCH secured, billable care minutes accelerating and a binding A$3 million facility agreement in place, Vitasora is positioned for its next phase of growth. Long-form financing documentation and funding conditions remain outstanding. The H1 2027 cash-flow breakeven objective is subject to execution, enrolments and collections.

ASX ANNOUNCEMENT

ASX:VHL

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Vitasora Health Limited
P: +61 408 462 873
E: marjan@vitasorahealth.com

Mr Nicholas Smedley
Non-Executive Chairman
Vitasora Health Limited
P: +61 447 074 160
E: nicholas@vitasorahealth.com

This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.

About Vitasora Health Limited - A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL) is redefining digital Connected Care in the U.S. healthcare market. We combine technology and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM), chronic care management (CCM), principal care management (PCM) and transitional care management (TCM) services support improved outcomes, reduced costs and stronger continuity of care between visits.

Partnering with healthcare providers and organisations, Vitasora extends care into the community through patient engagement, clinical care coordination, remote monitoring, documentation, reimbursement support and outcomes reporting. The Company's vCare platform is designed to bring these workflows together in one operating environment and support scalable delivery across multiple customer organisations.

Learn more at www.vitasorahealth.com

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora's current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates", "expects", "intends", "plans", "believes", "seeks", "estimates", "guidance" and similar expressions are intended to identify forward-looking statements and should be considered at-risk statements. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in building and scaling a healthcare services and technology business. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements except as required by law or by any appropriate regulatory authority.

Annexure — Peters Investments binding secured loan and option facility: principal terms

The following summarises principal commercial terms of the binding terms sheet with Peters Investments Pty Ltd. Long-form documentation is being finalised; the facility has not yet been funded and drawdown remains subject to applicable conditions and shareholder approvals.

Term	Details
Facility / lender	A$3,000,000 binding secured debt facility from Peters Investments Pty Ltd.
Status	Binding terms sheet; Drawdown of the facility conditional on entry into a formal loan agreement and agreement of the general security deed. Drawdown must occur by 10 November 2026.
Term	24 months.
Interest	12.5% per annum, compounded daily and paid monthly in cash.
Security	First-ranking General Security Deed, subject to shareholder approval under Listing Rule 10.1.
Principal repayment	Bullet repayment at maturity.
Early repayment	Permitted at any time; fee of 6% of principal repaid before maturity.
Options	208,971,000 options to acquire fully paid ordinary shares for a total issue price of A$1.00, subject to shareholder approval under Listing Rule 7.1 and adjusted for any consolidation before issue.
Exercise price	Initially A$0.012 per share.
Option term	Four years from issue.
Exercise-price reset	If the Company issues fully paid ordinary shares for cash below the prevailing exercise price, the exercise price reduces to that issue price, subject to a floor price of A$0.004 and ASX confirmation under Listing Rule 6.1.
Ownership outcome	Stated intention of 19.9% ownership on full exercise; subject to capitalisation, issue terms and legal verification. Options cannot be exercised to the extent this would breach the 20% takeover threshold contained in section 606 of the Corporations Act 2001 (Cth).
Potential dilution	Up to 208,971,000 ordinary shares on full exercise (on a pre-consolidation basis), subject to shareholder approval.
Potential proceeds	Approximately A$2,507,652 before costs at the initial A$0.012 exercise price if all options are exercised for cash; proceeds could be lower if reset applies.
Additional debt / security	Additional debt and security restricted without lender consent.
Change of control	Change-of-control protection included. If a person acquires voting power of more than 50% in the Company, the lender may require repayment within 10 business days.

Term	Details
Transaction costs	Company to reimburse the lender's reasonable legal costs, up to A$10,000 (plus GST).
Approvals / conditions	The Company is required to convene a general meeting of its shareholders within 3 months after drawdown to approve the security (Listing Rule 10.1, together with an independent expert's report) and the Options (Listing Rule 7.1). If either approval is not obtained, the loan, accrued interest and an amount equal to 6% of the loan amount are repayable within 30 days after the meeting.

Investor Definitions

Term	Meaning
Billable care minutes	Care time that meets applicable payer requirements and can support an eligible reimbursement claim; subject to final validation.
Hanging minutes	Care time recorded but not invoiceable because relevant monthly thresholds or other billing requirements have not been met.
Care Coordinator (CC)	Member of Vitasora's clinical care team supporting patient engagement, coaching, monitoring and documentation.
CC utilisation	Recorded productive care minutes relative to assumed available care capacity; methodology and denominator should be considered when comparing periods.
CPT codes	US procedure codes used to identify and bill eligible healthcare services.
CCM / PCM	Chronic Care Management / Principal Care Management: ongoing support for patients with qualifying chronic conditions.
RPM / TCM	Remote Patient Monitoring / Transitional Care Management.
FFS	Fee-for-service: payment for eligible services delivered and billed, rather than a fixed per-member fee.
vCare / EMR	Vitasora's care-management platform / electronic medical record.
THRIVE	Vitasora's patient coaching and engagement model.
Annualised run-rate	Illustrative extrapolation of a recent monthly or daily revenue level across 12 months; not a forecast or reported annual revenue.

Management operating/billing basis	Unaudited measure of estimated activity or revenue generated in a service period, which may differ from recognised accounting revenue and cash receipts.
Addressable patients	Patients potentially eligible for a service; not equivalent to actual enrolments or projected revenue.
Cash-flow breakeven	Point at which cash inflows cover cash outflows over the defined measurement period; distinct from accounting profitability.